Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Haemonetics (HAE) Receivables (2016 - 2025)

Haemonetics has reported Receivables over the past 16 years, most recently at $195.7 million for Q4 2025.

  • For Q4 2025, Receivables fell 7.66% year-over-year to $195.7 million; the TTM value through Dec 2025 reached $195.7 million, down 7.66%, while the annual FY2025 figure was $202.7 million, 1.89% down from the prior year.
  • Receivables for Q4 2025 was $195.7 million at Haemonetics, down from $207.1 million in the prior quarter.
  • Over five years, Receivables peaked at $213.5 million in Q3 2024 and troughed at $132.4 million in Q2 2021.
  • A 5-year average of $182.1 million and a median of $183.4 million in 2022 define the central range for Receivables.
  • Biggest five-year swings in Receivables: decreased 22.24% in 2021 and later rose 24.57% in 2022.
  • Year by year, Receivables stood at $145.7 million in 2021, then grew by 28.82% to $187.7 million in 2022, then grew by 12.74% to $211.6 million in 2023, then increased by 0.16% to $211.9 million in 2024, then dropped by 7.66% to $195.7 million in 2025.
  • Business Quant data shows Receivables for HAE at $195.7 million in Q4 2025, $207.1 million in Q3 2025, and $200.8 million in Q2 2025.